Uncategorized Archives - Page 10 of 145

FridayMay 23, 2025 9:00 am

Intelligent Bio Solutions Inc. (NASDAQ: INBS) Progressing with FDA Clearance for Fingerprint Drug Testing as Global Demand Grows

Intelligent Bio Solutions remains on track for a 2025 U.S. launch of its non-invasive Intelligent Fingerprinting Drug Screening System. The company’s FDA 510(k) submission included validation studies showing 94.1% accuracy in detecting opiates through fingerprint sweat. INBS is already active in 24 countries, with over 450 commercial accounts globally, and adoption growing across diverse industries, including logistics, mining, retail, and marine operations. The firm is expanding its distributor network to support localized growth ahead of its U.S. market entry. Intelligent Bio Solutions (NASDAQ: INBS), a medical technology company specializing in rapid, non-invasive testing solutions, is preparing for its expected U.S.…

ThursdayMay 22, 2025 10:30 am

Nutriband Inc. (NASDAQ: NTRB) Charts Path to Commercialization

AVERSA Fentanyl has potential to become the world’s first opioid pain patch with abuse deterrent properties, CEO states in report Nutriband and Kindeva Drug Delivery have formalized a strong product-development partnership and long-term commitment Other key steps outlined as company works to develop, scale-up manufacturing process to bring Aversa technology closer toward commercialization In a recent report to shareholders, Nutriband (NASDAQ: NTRB) CEO Gareth Sheridan shared significant company achievements and milestones as well as his expectations for 2025 (https://ibn.fm/9K5zT). At the center of the company’s positive outlook for future is noteworthy progress made toward the commercialization of its proprietary Aversa technology, including…

WednesdayMay 21, 2025 9:00 am

Adageis Offers Easy-to-Use AI-Driven Solution to Help Healthcare Providers Unlock High-Value Care, Maximize Revenue

Adageis delivers a user-friendly platform that helps providers identify high-value services while improving care quality. The company’s patented ProActive Care Platform leverages AI to shift providers from fee-for-service to value-based care models. The system integrates seamlessly with major EHR platforms to enhance operations without disrupting workflows. Adageis supports over 260,000 patient lives and expects that figure to more than double by the end of Q2 2025. The company is helping providers better understand insurance contract value and advocate for appropriate reimbursement. For healthcare practices navigating the shift toward value-based care, the complexity of insurance contracts, quality metrics, and data reporting…

TuesdayMay 20, 2025 9:45 am

Intelligent Bio Solutions Inc. (NASDAQ: INBS) Targets Global Sales Growth with Multilingual Digital Rollout

Medical technology company Intelligent Bio Solutions has launched Arabic, Italian, and Spanish websites to support expansion into key international markets. The move opens digital access to over 1.4 billion people across Latin America, the Middle East, and Southern Europe. The rollout aligns with increased demand for non-invasive workplace drug testing and compliance tools. INBS’s flagship fingerprint sweat-based drug screening system is currently used by over 450 clients in 24 countries. The company plans a U.S. market launch in 2025 as it continues to develop additional biosensor applications. Intelligent Bio Solutions (NASDAQ: INBS), a medical technology company specializing in rapid, non-invasive…

TuesdayMay 20, 2025 9:00 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Is ‘One to Watch’

NRx Pharmaceuticals is advancing a pipeline of innovative therapies targeting multibillion-dollar unmet needs in central nervous system disorders. The company’s lead candidate, NRX-100 (preservative free IV ketamine), NDA in process with the FDA, has been granted Fast Track designation by the FDA for acute suicidal depression, and a patent for this novel formulation has been filed with the U.S. Patent and Trademark Office. NRX-101 (oral D-cycloserine/lurasidone), has received FDA Breakthrough Therapy designation, expediting its development. HOPE Therapeutics, NRx’s interventional psychiatry subsidiary, is targeting $100M in forward looking revenue by year-end 2025, through development of a national clinic network treating suicidal depression,…

MondayMay 19, 2025 2:30 pm

Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform

Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, is part of a rising wave of Republican lawmakers advocating for the therapeutic use of psychedelics to treat PTSD, depression, and suicidality among veterans—a movement recently spotlighted by The Wall Street Journal. After undergoing ibogaine and DMT therapy in Mexico in 2018, Luttrell described the experience as transformative, helping him confront trauma and save his marriage. Now in Congress, he’s pushing for science-based, medically supervised access to Schedule I drugs like ibogaine, psilocybin, and MDMA. Joined by fellow veterans in office, including Rep. Dan Crenshaw (R-Texas) and Rep. Jack Bergman (R-Mich.), Luttrell…

MondayMay 19, 2025 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Reports Q1 Milestones, Financial Results

Q1 milestones are representative of Soligenix’s commitment to advance its pipeline of therapeutic candidates, focusing on areas with significant unmet medical needs. The company noted positive interim results from the ongoing open-label, investigator-initiated study (“IIS”) evaluating extended HyBryte(TM) treatment. Soligenix announced the release of a publication describing the preclinical efficacy of CiVax(TM), a thermostabilized subunit vaccine against SARS-CoV-2. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company dedicated to developing and commercializing treatments for rare diseases, recently announced its financial results for the first quarter of 2025, alongside a summary of the company’s latest accomplishments (https://ibn.fm/OMQmM). These milestones are representative of Soligenix’s continued…

MondayMay 19, 2025 9:00 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Names Experienced Life Science Leader as New CEO

Experienced leadership contributes to key performance indicators. Dr. Eric Poma brings more than 30 years of experience to his new role as CLDI CEO. His expertise will help the company develop and advance proprietary groundbreaking therapies. Effective leadership is a cornerstone of organizational success, particularly in the dynamic and high-stakes realm of biotechnology. Recognizing the pivotal role of seasoned leadership, Calidi Biotherapeutics (NYSE American: CLDI) has announced the appointment of Eric Poma, PhD, as its new Chief Executive Officer and member of the board of directors (https://ibn.fm/qMEu4). This strategic transition underscores Calidi’s commitment to advancing its innovative cancer therapies under experienced guidance. Dr.…

TuesdayMay 13, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Pioneers Innovative Approach to Opioid Crisis with Game-Changing Transdermal Patch

The opioid epidemic has prompted a re-evaluation of pain-management strategies, highlighting the importance of balancing effective treatment with abuse prevention Nutriband’s AVERSA(TM) Fentanyl represents a significant advancement in this domain The company’s strategic development of AVERSA Fentanyl follows a structured pharmaceutical lifecycle As the opioid crisis continues to challenge public health systems, the need for innovative solutions has become increasingly apparent. Rather than relying solely on restrictive measures, companies such as Nutriband (NASDAQ: NTRB) are exploring technological advancements to mitigate abuse while ensuring patient access to necessary medications. Nutriband’s development of AVERSA(TM) Fentanyl, an abuse-deterrent transdermal patch, exemplifies this forward-thinking approach (https://ibn.fm/jhHMY). The…

FridayMay 09, 2025 9:00 am

Nutriband Inc. (NASDAQ: NTRB) Innovating Abuse-Deterrent Drug Delivery in a Shifting Opioid Landscape

Nutriband’s AVERSA(TM) technology is advancing toward commercialization as the first abuse-deterrent transdermal fentanyl patch Recent FDA regulatory changes underscore the urgent need for safer opioid delivery methods and responsible prescribing Strategic milestones with partner Kindeva and a strengthened global IP portfolio position Nutriband for long-term growth A Market Demanding Safer Opioid Solutions The opioid crisis remains a critical public health challenge in the U.S. and globally, prompting a series of new regulatory measures designed to improve safety and reduce misuse. In early 2025, the FDA approved Journavx (suzetrigine), a first-in-class non-opioid painkiller offering patients safer alternatives to opioids. Additionally, opioid…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Intelligent Bio Solutions Inc. (NASDAQ: INBS) Progressing with FDA Clearance for Fingerprint Drug Testing as Global Demand Grows

Nutriband Inc. (NASDAQ: NTRB) Charts Path to Commercialization

Adageis Offers Easy-to-Use AI-Driven Solution to Help Healthcare Providers Unlock High-Value Care, Maximize Revenue

Intelligent Bio Solutions Inc. (NASDAQ: INBS) Targets Global Sales Growth with Multilingual Digital Rollout

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Is ‘One to Watch’

Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform

Soligenix Inc. (NASDAQ: SNGX) Reports Q1 Milestones, Financial Results

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Names Experienced Life Science Leader as New CEO

Nutriband Inc. (NASDAQ: NTRB) Pioneers Innovative Approach to Opioid Crisis with Game-Changing Transdermal Patch

Nutriband Inc. (NASDAQ: NTRB) Innovating Abuse-Deterrent Drug Delivery in a Shifting Opioid Landscape

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search